About Our Company

ACEA Therapeutics is a clinical stage pharmaceutical company with a diverse product portfolio to address unmet medical needs in cancer, autoimmune disease, and Covid-19.

Alongside a robust R&D and clinical organization, ACEA has established drug manufacturing and commercial capabilities in China to support our long-term growth. This infrastructure provides us with greater control over our supply chain for timely delivery of highest quality products to patients

Our lead compound, Olgotrelvir, a small molecule dual inhibitor of SARS-CoV-2 main protease (M^pro) and human cathepsin L, has been developed as a standalone oral medication for the treatment of COVID-19. A pivotal Phase III clinical trial of more than 1200 COVID-19 patients treated with Olgotrelvir or placebo has been recently completed. 

Abivertinib, a small molecule kinase inhibitor, has completed Phase II EGFR T790M+ NSCLC study in China with positive results published in Clinical Cancer Research. Recently FDA granted IND clearance for Phase II study of Avivertinib to treat patients resistant to the NSCLC drug Tagrisso (Osimertinib).

Two more novel small molecule kinase inhibitors are in clinical stage. AC0058, a Bruton’s tyrosine kinase (BTK) inhibitor, has entered Phase Ib development in the US for the treatment of systemic lupus erythematosus (SLE). AC0939, a novel small molecule inhibitor of FMS-like tyrosine kinase 3 (FLT3), has reached Phase I development in China for the treatment of acute myeloid leukemia (AML).

ACEA also has large molecule and cell therapy products under clinical development. An antibody drug-conjugate that targets CD38, STI-6129 has entered Phase Ib development in the US and China for the treatment of AL amyloidosis and multiple myeloma. STI-1492, a gene modified T cell therapy targeting cancer cells overexpressing CD38, has been approved for Phase I study in patients with relapsed or refractory multiple myeloma.

Multiple other investigational drug candidates including small molecule, large molecule and cell therapy programs are currently in development for the treatment of cancer, autoimmune diseases, and Covid-19. With the diverse portfolio and drug development milestones, ACEA is well-positioned to fulfill the promise to deliver innovative treatments to patients, while creating value for shareholders, employees, and society.